Dosage form: Oil solution for Injection
Pharmacotherapeutic group: Anabolic substance for systematic application. Anabolic steroids. ATC code A14A A02.
Stanazolol is an anabolic steroid, derivative of androstane (dihydrotestosterone). Stanozolol is a progesterone antagonist. Nevertheless, the drug protects against the action of progestogen nandrolone. It penetrates into the cell nucleus and activates the genetic apparatus of the cell, resulting in increased synthesis of DNA, RNA and structural proteins, enzyme activation circuit tissue respiration and increased cell respiration, the oxidative phosphorylation, ATP synthesis and accumulation macroergs intracellularly.
Stanobolic leads to increased muscle mass, decreased fat deposition, improving tissue trophism, and promotes the deposition of calcium in the bones; the body retains nitrogen, phosphorus, sulfur, potassium, sodium and water. Hematopoietic effects associated with increased synthesis of erythropoietin.
Indications for REFERENCE:
Exhaustion of different types, violation of protein metabolism after severe injuries, infectious diseases, burns, major surgery, radiotherapy; osteoporosis of various genesis, progressive muscular dystrophy; myopathy and prevention of osteoporosis during treatment with corticosteroids; slow formation of callus after fractures, azoticty negative balance in corticosteroid therapy, hypo- and aplastic anemia.
Prophylactically to reduce the frequency and severity of attacks of hereditary angioedema. Adjunct in the treatment of tuberculosis, osteomyelitis, asthma, hepatitis.